Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing cancer prevalence
3.2.1.2 Patent expirations
3.2.1.3 Growing government support towards generics
3.2.1.4 Rising demand for personalized treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 Maintaining consistent quality standards
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Reimbursement scenario
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Chemotherapy drugs
5.3 Targeted therapy drugs
5.4 Immunotherapy drugs
5.5 Hormonal therapy drugs
5.6 Other drug types
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Prostate cancer
6.3 Lung cancer
6.4 Breast cancer
6.5 Colorectal cancer
6.6 Leukemia
6.7 Other indications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 22021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Topical
7.4 Injectable
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 202021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 The Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Apotex Inc.
10.3 AstraZeneca
10.4 Biocon Ltd.
10.5 Gland Pharma Limited
10.6 Incyte Corporation
10.7 Lupin Pharmaceuticals, Inc.
10.8 Mylan N.V.
10.9 Natco Pharma Ltd.
10.10 Novartis Pharmaceuticals Corporation
10.11 Pfizer Inc.
10.12 Regeneron Pharmaceuticals Inc.
10.13 Synthon Pharmaceuticals, Inc.
10.14 Teva Pharmaceuticals
10.15 Zydus Lifesciences Limited
